Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two‐year radiographic and clinical outcomes
Mark C. Genovese(Eli Lilly (United States)), Barbara Finck(Coherus BioSciences (United States)), Joan M. Bathon(Columbia University Irving Medical Center), Roy Fleischmann(Metroplex Clinical Research Center), Michael Schiff(Denver Arthritis Clinic), John Tesser(Arizona Research Center), Larry W. Moreland(University of Pittsburgh), Joseph A. Markenson(Hospital for Special Surgery), Mary Chester Wasko(Allegheny Health Network), Edward Keystone(University of Toronto), Grant W. Cannon(University of Utah), Richard W. Martin(Grand Rapids Community College), Arthur L. Weaver(University of Nebraska Medical Center), G Spencer-Green(Vertex Pharmaceuticals (United States))
Cited by 733
Related Papers
2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
|Arthritis Care & Research|2012|1.8k
A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis
|New England Journal of Medicine|2000|1.8k
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial
|The Lancet|2000|1.5k
Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry
|Nature Immunology|2019|1.4k
Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition
|New England Journal of Medicine|2005|1.2k